2013 NIH Workshop on Protein Homeostasis and Viral Infection

Investigator: Raul Andino-Pavlovsky, PhD
Sponsor: NIH National Institute of Allergy and Infectious Disease

Location(s): United States


Protein Homeostasis & Viral Infection: from Mechanisms to Therapeutics September 18 & 19, 2013 

Does the stress of viral protein production during infection represent a therapeutic opportunity? This NIH Workshop will explore the role of protein homeostasis in viral infection and the potential to exploit related aspects of the host-virus relationship to develop novel antiviral therapeutics.

Talks by:

Ari Helenius (ETH): Overview of viral protein synthesis and quality control

Ineke Braakman (Utretcht University): Folding in the ER of viral proteins

Yoshi Matuura (Osaka University): Hsp90 and TRiC in HCV replication

Sandra Weller (Univ. of Connecticut): Viruses and VICE

Christian Schlieker (Yale): Ubiquitin pathway and virus assembly

Rick Morimoto (Northwestern Univ.): Overview of protein homeostasis networks

Judith Frydman (Stanford): Chaperones and pathogenesis

Nevan Krogan (UCSF): Mapping interactions between virus and host

Raul Andino (UCSF): Genetic structure and adaptation of virus populations 

Santiago Elena (Spain National Research Council): Maintenance of genetic diversity in RNA viruses

 Jeff Kelly (Scripps): Overview of protein homeostasis as a therapeutic target

 Len Neckers (NCI): Hsp90 as a molecular target - background and rationale

 Jason Gestwicki (UCSF): Hsp70 inhibitors

Daniel Finley (Harvard):  Therapeutics using proteasome inhibitors

William Balch (Scripps): Hsp90/AHA1 inhibitors

David Proia (Synta Pharmaceuticals): Hsp 90 inhibitors

Jane Trepel (NCI): Hsp 90 inhibitors in the clinic

Andres McAllister (Debiopharm, Switzerland): Prolyl isomerase inhibitors as antivirals

Jeff Cohen (NIAID): Hsp 90 inhibitors against EBV

Jeff Brodsky (U. Pittsburgh): Identification of novel inhibitors of large T antigen as therapeutics for polyoma virus replication

Walter Storkus (U. Pittsburgh): Hsp 90 inhibitors and host immune response